Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- ChecktodayChange DetectedThe page has removed a citation for a clinical trial regarding Cabozantinib versus Sunitinib for metastatic renal cell carcinoma, which included important erratum details.SummaryDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to reflect a new version of the study, now labeled as v2.15.0, and includes the addition of the term 'Metastatic Renal Cell Carcinoma' and the collaborator 'Merck Sharp & Dohme LLC'.SummaryDifference37%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 13, 2025, while a date for March 25, 2025, has been removed.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version (v2.14.3) and a more recent last update date of March 25, 2025, replacing the previous version (v2.14.2) and last update date of March 13, 2025.SummaryDifference0.1%
- Check51 days agoChange DetectedThe page has been updated with new dates for events, specifically adding March 2025 dates while removing previous February 2024 dates. The status of recruitment has also been clarified.SummaryDifference0.8%
Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.